Homocysteine research: Alive and kicking!

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1571-1574

  Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; LEVODOPA; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; VITAMIN B GROUP;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA METABOLISM; DNA METHYLATION; DNA SYNTHESIS; DRUG MEGADOSE; EPILEPSY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK REDUCTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN DEFICIENCY;

BIOMEDICAL RESEARCH; HOMOCYSTEINE; HUMANS;

EID: 36849023119     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.359     Document Type: Conference Paper

References (35)

1. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clin Chem Lab Med 2007;45:1575-81.
2. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc 2004;291:565-75.
3. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
4. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
5. Wald DS. Folic acid, homocysteine and cardiovascular disease - judging causality in the face of inconclusive trial evidence. World Congress on Hyperhomocysteinemia. Clin Chem Lab Med 2007;45:A17, Abstract 106.
6. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
7. Clarke R. Homocysteine-lowering trials for prevention of coronary heart disease and stroke. World Congress on Hyperhomocysteinemia. Clin Chem Lab Med 2007;45:A3.
8. Spence JD. Vitamin Intervention for Stroke Prevention Trial: an efficacy analysis. World Congress on Hyperhomocysteinemia. Clin Chem Lab Med 2007;45:A3.
9. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, Van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
10. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108-16.
11. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-6.
12. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-86.
13. Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996;143:658-64.
14. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43.
15. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention for Stroke Prevention Trial: an efficacy analysis. Stroke 2005;36:2404-9.
16. Spence JD. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial. Clin Chem Lab Med 2007;45:1582-5.
17. Herrmann W, Herrmann M, Joseph J, Tyagi SC. Homocysteine, brain natriuretic peptide and chronic heart failure, a critical review. Clin Chem Lab Med 2007;45:1633-44.
18. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5:167-73.
19. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. J Am Med Assoc 2003;289:1251-7.
20. Herrmann M, Taban-Shoma O, Hubner U, Pexa A, Kilter H, Umanskaya N, et al. Hyperhomocysteinemia and myocardial expression of brain natriuretic peptide in rats. Clin Chem 2007;53:773-80.
21. Joseph J, Washington A, Joseph L, Kennedy RH. Hyperhomocysteinaemia- induced atrial remodelling in hypertensive rats. Clin Exp Pharmacol Physiol 2004;31:331-7.
22. Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and neuropsychiatric diseases. Clin Chem Lab Med 2007;45:1590-1606.
23. McCaddon A. Homocysteine and cognitive impairment; a case series in a general practice setting. Nutr J 2006;5:6.
24. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006;580:2994-3005.
25. Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, et al. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem 2007;53:1129-36.
26. Ramsaransing GS, Fokkema MR, Teelken A, Arutjunyan AV, Koch M, De KJ. Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:189-92.
27. Apeland T, Mansoor MA, Strandjord RE, Kristensen O. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. Acta Neurol Scand 2000;101:217-23.
28. Freed WJ. Selective inhibition of homocysteine-induced seizures by glutamic acid diethyl ester and other glutamate esters. Epilepsia 1985;26:30-6.
29. 12 deficiencies in osteoporosis - a systematic review. Clin Chem Lab Med 2007;45:1621-32.
30. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
31. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.
32. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
33. Herrmann M, Wildemann B, Claes L, Klohs S, Ohnmacht M, Taban-Shomal O, et al. Experimental hyperhomocysteinemia reduces bone quality in rats. Clin Chem 2007;53:1455-61.
34. Jamaluddin MS, Chen I, Yang F, Jiang X, Jan M, Liu X, et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007;110:3648-55. Epub Aug 13.
35. Alonso-Aperte E, Gonzalez MP, Poo-Prieto R, Varela-Moreiras G. Folate status and S-adenosylmethionine/ S-adenosylhomocysteine ratio in colorectal adenocarcinoma in humans. Eur J Clin Nutr 2007;Epub ahead of print.